It is illegal to market drugs that are not FDA-approved for a specific condition. This criminal offense is called off-label marketing. Yet, 2 million children are currently being prescribed psychiatry's most...
created by Kevin Hall | 33 wks ago | updated 29 wks ago 1130 views | 42 recommendations | 21 comments
As dementia patient numbers rise and the search for early diagnosis and better treatment continues disturbing news is emerging around life expectancy for those being administered antipsychotic drugs."The lives of...
The man was suffering serious mental health issues, and a lawsuit
showed the state was partially to blame for not providing medication
that he was trying to take when he suffered a psychotic break and murdered his parents. Now he's trying to get some of the inheritance money...
In Massachusetts, over 10% of children in the Department of Social Services are being forced to take at least three psychiatric drugs at a time. Also, 19% of
DSS kids are on antidepressants, 9% on antipsychotics, 21% on ADHD drugs and 13%
on mood stabilizers,...
"Part of the criticism of Biederman speaks to a deeper issue in psychiatry: the extensive financial ties between the drug industry and researchers. Biederman has received research funding from 15 drug companies and serves as a paid speaker or adviser to seven of them,...
created by Boston | 2 years ago 349 views | 0 recommendations | 0 comments
I remember one of my Madison Avenue friends once saying that you never
own your brand. Your brand exists in the minds of your customers. It
now also exists on their YouTube accounts and the big...
created by mtippett | 2 years ago | updated 2 years ago 834 views | 17 recommendations | 3 comments
"Instead of offering the promise of reducing violence, all psychiatric drugs carry the potential risk of driving the individual into violent madness. For example, both the newer antidepressants such as Prozac, Paxil, Zoloft and Celexa, and the antipsychotic drugs such as...
created by Boston | 2 years ago 330 views | 0 recommendations | 0 comments